Ginkgo Bioworks
PublicGinkgo Bioworks is now publicly traded
The data on this page reflects Ginkgo Bioworks's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 16, 2021
Last Round
Series E
Extension
May 28, 2020
Total Funding Raised
$2.42B
Company Overview
Ginkgo Bioworks operates in Biotech and is based in Boston, Massachusetts. Its recorded funding history includes a Series E Extension round in May 2020.
Ginkgo Bioworks is a biotechnology company that offers comprehensive cell programming solutions to address challenges in various sectors, including food, agriculture, pharmaceuticals, and industrial chemicals.
Sector
Biotech
AI Layer
Infrastructure
Ginkgo Bioworks Comparables
Compare Ginkgo Bioworks with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bacchus Bio innovation Co., Ltd. | 72% | |
| CynosBio, Inc. | 62% | |
| Basecamp Research | 60% |
For institutional investors. Book with your work email.
Ginkgo Bioworks Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 16, 2021 | ||||
| Series E Extension | May 28, 2020 | ||||
| Series E | Sep 19, 2019 | ||||
| Series D | Dec 14, 2017 | ||||
| Series C | Jun 8, 2016 | ||||
Series B | Jul 23, 2015 |
For institutional investors. Book with your work email.
Ginkgo Bioworks Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cascade Investment Group | Series C, Series D |
| Cascade Investment | Series C, Series D, IPO, Series E |
| Massachusetts Development Finance Agency | Series A |
| Allen & Company LLC | Series C |
| Bellco Capital | IPO |
| ArrowMark Partners | IPO |
| Collaborative Fund | Series A, Seed |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueOct 21, 2026
Ginkgo Bioworks, Inc reports $20.2M in quarterly revenue, below the $24.05M estimate, on Oct 21st '26.
- has_revenueOct 9, 2026
Ginkgo Bioworks, Inc reports $20.16 million in quarterly revenue, missing the $24.1M estimate.
- partners_withOct 8, 2026
Ginkgo Bioworks, Inc partners with National Science Foundation through the Programmable Cloud Laboratories Test Bed program, with Ginkgo Bioworks, Inc expected to provide Reconfigurable Automation Carts and software to cloud lab nodes at Caltech, the University of Maryland, and Northwestern University.
- partners_withSep 17, 2026
On Sep 17th '26, Ginkgo Bioworks, Inc and Lilly Group enter a new agreement under which Ginkgo Bioworks, Inc provides discovery data generation services, including small molecule and antibody developability testing, to companies on Lilly Group's platform.
For institutional investors. Book with your work email.
Ginkgo Bioworks Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.